A New Understanding of Pancreatic Cancer: Why Precursor Lesions Don’t Always Become Malignant
For years, researchers operated under a clear assumption: as precancerous cells in the pancreas evolved, they would inevitably command their surrounding environment to support their growth. A groundbreaking study published in Cancer Discovery has now shattered that paradigm, revealing that the transition from a precursor lesion to a deadly tumor is far more complex than previously thought.
By studying more than 150 donor pancreases, researchers at the University of Michigan’s Rogel and Blondy Center for Pancreatic Cancer discovered that the microenvironment surrounding precancerous lesions—known as pancreatic intraepithelial neoplasia (PanIN)—remains remarkably similar to that of a healthy pancreas. These early-stage lesions fail to “recruit” the surrounding cells to act as helpers, a critical step that fully malignant tumors eventually master.
“It turns out, the microenvironment of these precursor lesions is the same as the microenvironment of the normal pancreas. The lesions have not convinced any of the cells around them to change. That’s not what we were expecting. We were expecting the two components, the cells and the microenvironment, to evolve in lockstep. They did not.”
— Marina Pasca di Magliano, Ph.D., co-senior study author
The “Needle in a Haystack” Approach to Cancer Research
Historically, isolating these microscopic lesions has been a significant hurdle. Often, these findings were only available after a patient underwent surgery to remove a primary tumor, which likely altered the surrounding tissue. By partnering with Gift of Life Michigan, the research team gained access to healthy donor pancreases, allowing them to study PanIN lesions in a more natural state across a wide age range of donors.
Using advanced technologies like single-cell RNA sequencing and spatial transcriptomics, the scientists were able to focus specifically on the “needles in the haystack.” According to co-senior author Timothy Frankel, M.D., these methods allow researchers to map gene expression at a granular level, providing a level of detail that was previously impossible to achieve with traditional bulk analysis.
What Triggers the Malignant Shift?
If these precursor lesions are relatively common, even in younger individuals, why do they rarely progress to cancer? This study suggests that the “tumor microenvironment”—the network of fibroblasts and immune cells that typically fuel cancer growth—is not present in the early stages. This implies that some additional catalyst is required to bridge the gap between a benign lesion and a malignant tumor.
Researchers are now looking toward external stressors, such as:
- Chronic inflammation and pancreatitis
- Environmental factors like smoking
- Metabolic conditions, including obesity
- The natural aging process
Understanding how these factors “flip the switch” on the microenvironment is the next frontier. If scientists can identify the exact mechanisms that allow these lesions to seize control of their surroundings, they may be able to develop interventions to intercept the process before cancer takes hold.
Frequently Asked Questions (FAQ)
Why is it so hard to study early pancreatic lesions?
PanIN lesions are microscopic and often hidden within the pancreas. Historically, they were only identified when a researcher was already examining a large, malignant tumor, which complicates the ability to see how the lesion behaved before the tumor developed.
What does “asynchronous evolution” mean in this study?
It refers to the finding that the cancer cells and their surrounding environment do not evolve together. While the lesion itself may show early genetic changes, the surrounding “microenvironment” remains healthy, unlike the supportive environment found in fully formed tumors.
Could this lead to new cancer prevention strategies?
Yes. By identifying the specific stressors that trigger the transformation of the microenvironment, researchers hope to develop new therapies that stop the conversion of precancerous cells into malignant ones.
Did you know?
This research was a massive collaborative effort involving experts in bioinformatics and pathology from the University of Maryland School of Medicine and New York University, alongside the team at the University of Michigan.
Want to stay updated on the latest breakthroughs in cancer research? Subscribe to our newsletter for deep dives into the science that is changing the future of medicine. Have questions about this study? Drop a comment below and join the discussion.